Titlebook: Biomarkers for Huntington‘s Disease; Improving Clinical O Elizabeth A. Thomas,Georgia M. Parkin Book 2023 The Editor(s) (if applicable) and

Obligatory

項(xiàng)目

Extracellular Vesicles as Possible Sources of Huntington’s Disease Biomarkersnthesis, lipids, proteins, nucleic acids, metabolites and other molecules of the EV producing cell are incorporated into EVs. EVs are able to transfer such molecular cargo to recipient cells and thus participate in intercellular communication. In this chapter, we review the current knowledge about E

instate

Saliva as a Relevant Biofluid for Huntington’s Disease Biomarker Researchritical advances in biomarker discovery for neurodegenerative diseases, such as Huntington’s disease, a progressive, inherited disease associated with disrupted motor abilities and cognitive decline. Nonetheless, there remains a need for biomarkers that can be reliably measured in more easily-access

FATAL

Retinal Imaging and Functional Biomarkers of Huntington’s Diseasee only portion of the central nervous system that is optically accessible for high-resolution imaging. Over the last several decades there has been significant interest in leveraging the optical accessibility of the retina to understand, diagnose and monitor neurological diseases such as Huntington’

pancreas

Positron Emission Tomography (PET) Imaging Biomarkers in Huntington’s Diseaseprotein (mHTT). People with HD (pwHD) suffer from progressive neuronal cell loss in the striatum and cortex, causing progressive motor impairments, psychiatric symptoms, and cognitive impairment. HD symptoms can partially be explained by the disruption of a wide variety of molecular processes. Monit

MAG

Functional and Physiological MRI Measures as Early Biomarkers for Huntington’s Diseasegenesis of HD is progressive with a long premanifest phase in which subtle changes in the brain occur up to two decades before the onset of clinical symptoms. Early biomarkers reflecting the subtle changes in the HD brain for better understanding disease progression and evaluating treatment efficacy

轉(zhuǎn)折點(diǎn)

Metabolomics in Huntington’s DiseaseThe present chapter contains an introduction to the field of metabolomics as well as a comprehensive summary of the literature describing metabolomics and lipidomics in HD to date, divided in two sections covering animal and cell model studies and human studies with more than 30?studies?discussed in

有幫助

必死

Ingenuity

Inflammation Biomarkers in Huntington’s Diseaseand treatment of neurodegenerative diseases, and inflammatory markers are suggested important tools to identify disease risk, diagnose disease, monitor disease progression or treatment response, as well as predict clinical outcomes. In Huntington’s disease (HD) inflammatory processes, both centrally